Tags

Type your tag names separated by a space and hit enter

Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Hum Vaccin Immunother. 2014; 10(10):2795-8.HV

Abstract

The combined diphtheria-tetanus-acellular pertussis-hepatitis B-poliomyelitis/Haemophilus influenza vaccine (DTPa-HBV-IPV/Hib: Infanrix™ hexa, GlaxoSmithKline Vaccines) is used for primary vaccination of infants in a range of schedules world-wide. Antibody persistence after 4 DTPa-HBV-IPV/Hib doses in the first 2 y of life has been documented, but long-term persistence data following the 3, 5, 11-12 months (3-5-11) infant vaccination schedule, employed for example in Nordic countries, are limited. We assessed antibody persistence in 57 5-year-old children who had received either DTPa-HBV-IPV/Hib or DTPa-IPV/Hib (Infanrix™-IPV/Hib, GlaxoSmithKline Vaccines) in the 3-5-11 schedule. Among DTPa-HBV-IPV/Hib recipients, 7/12 retained seroprotective antibody concentrations for diphtheria, 10/12 for tetanus, 5/12 for hepatitis and 10/12 for Hib. Detectable antibodies were observed for 0/12 children for pertussis toxin (PT), 12/12 for filamentous haemagglutinin (FHA) and 8/12 for pertactin (PRN). Among DTPa-IPV/Hib recipients, 28/45 retained seroprotective anti-diphtheria concentrations, 34/44 for tetanus and 40/45 for Hib. Detectable antibodies were observed for 9/45 children for PT, 41/45 for FHA and 34/45 for PRN. Antibody persistence in DTPa-HBV-IPV/Hib and DTPa-IPV/Hib-vaccinees appeared similar in 5 y olds to that previously observed in children of a similar age who had received 4 prior doses of DTPa-HBV-IPV/Hib (or DTPa-IPV/Hib). As in subjects primed with 4 prior doses, we observed that antibodies markedly declined by 5 y of age, calling for the administration of a pre-school booster dose in order to ensure continued protection against pertussis.

Authors+Show Affiliations

a Department of Clinical Sciences; Pediatrics ; Umeå University ; Umeå , Sweden.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25483640

Citation

Silfverdal, Sven A., et al. "Immunological Persistence in 5 Y Olds Previously Vaccinated With Hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 Months of Age." Human Vaccines & Immunotherapeutics, vol. 10, no. 10, 2014, pp. 2795-8.
Silfverdal SA, Assudani D, Kuriyakose S, et al. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age. Hum Vaccin Immunother. 2014;10(10):2795-8.
Silfverdal, S. A., Assudani, D., Kuriyakose, S., & Van Der Meeren, O. (2014). Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age. Human Vaccines & Immunotherapeutics, 10(10), 2795-8. https://doi.org/10.4161/21645515.2014.970494
Silfverdal SA, et al. Immunological Persistence in 5 Y Olds Previously Vaccinated With Hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 Months of Age. Hum Vaccin Immunother. 2014;10(10):2795-8. PubMed PMID: 25483640.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age. AU - Silfverdal,Sven A, AU - Assudani,Deepak, AU - Kuriyakose,Sherine, AU - Van Der Meeren,Olivier, PY - 2014/12/9/entrez PY - 2014/12/9/pubmed PY - 2015/9/12/medline KW - CI, confidence interval KW - DTPa-HBV-IPV/Hib, - diphtheria-tetanus-acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine KW - DTPa-IPV/Hib, diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b vaccine KW - FHA, filamentous haemagglutinin KW - GMC, geometric mean antibody concentration KW - HBs, anti-hepatitis B surface antigen KW - Hib, Haemophilus influenzae type b KW - NA, not applicable KW - PRN, pertactin KW - PRP, polyribosylribitol phosphate KW - PT, pertussis toxin KW - antibody persistence KW - booster KW - vaccination schedule KW - vaccine KW - μg/ml, micrograms per milliliter SP - 2795 EP - 8 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 10 IS - 10 N2 - The combined diphtheria-tetanus-acellular pertussis-hepatitis B-poliomyelitis/Haemophilus influenza vaccine (DTPa-HBV-IPV/Hib: Infanrix™ hexa, GlaxoSmithKline Vaccines) is used for primary vaccination of infants in a range of schedules world-wide. Antibody persistence after 4 DTPa-HBV-IPV/Hib doses in the first 2 y of life has been documented, but long-term persistence data following the 3, 5, 11-12 months (3-5-11) infant vaccination schedule, employed for example in Nordic countries, are limited. We assessed antibody persistence in 57 5-year-old children who had received either DTPa-HBV-IPV/Hib or DTPa-IPV/Hib (Infanrix™-IPV/Hib, GlaxoSmithKline Vaccines) in the 3-5-11 schedule. Among DTPa-HBV-IPV/Hib recipients, 7/12 retained seroprotective antibody concentrations for diphtheria, 10/12 for tetanus, 5/12 for hepatitis and 10/12 for Hib. Detectable antibodies were observed for 0/12 children for pertussis toxin (PT), 12/12 for filamentous haemagglutinin (FHA) and 8/12 for pertactin (PRN). Among DTPa-IPV/Hib recipients, 28/45 retained seroprotective anti-diphtheria concentrations, 34/44 for tetanus and 40/45 for Hib. Detectable antibodies were observed for 9/45 children for PT, 41/45 for FHA and 34/45 for PRN. Antibody persistence in DTPa-HBV-IPV/Hib and DTPa-IPV/Hib-vaccinees appeared similar in 5 y olds to that previously observed in children of a similar age who had received 4 prior doses of DTPa-HBV-IPV/Hib (or DTPa-IPV/Hib). As in subjects primed with 4 prior doses, we observed that antibodies markedly declined by 5 y of age, calling for the administration of a pre-school booster dose in order to ensure continued protection against pertussis. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/25483640/Immunological_persistence_in_5_y_olds_previously_vaccinated_with_hexavalent_DTPa_HBV_IPV/Hib_at_3_5_and_11_months_of_age_ L2 - https://www.tandfonline.com/doi/full/10.4161/21645515.2014.970494 DB - PRIME DP - Unbound Medicine ER -